These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7356232)

  • 1. Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy.
    Stote RM; Smith LH; Dubb JW; Moyer TP; Alexander F; Roth JL
    Ann Intern Med; 1980 Mar; 92(3):384-5. PubMed ID: 7356232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xanthine-containing calculi during allopurinol therapy.
    Kranen S; Keough D; Gordon RB; Emmerson BT
    J Urol; 1985 Apr; 133(4):658-9. PubMed ID: 3981718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine) and oxypurinol after rigorous exercise.
    Kaya M; Moriwaki Y; Ka T; Inokuchi T; Yamamoto A; Takahashi S; Tsutsumi Z; Tsuzita J; Oku Y; Yamamoto T
    Metabolism; 2006 Jan; 55(1):103-7. PubMed ID: 16324927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?
    Mertz DP; Eichhorn R
    Klin Wochenschr; 1984 Dec; 62(24):1170-2. PubMed ID: 6530890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous determination of allopurinol, oxipurinol and uric acid in human plasma by high-performance liquid chromatography.
    Nissen P
    J Chromatogr; 1982 Mar; 228():382-6. PubMed ID: 7076766
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of glucagon on renal excretion of oxypurinol and purine bases.
    Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Hiroishi K; Yamakita J; Nakano T; Higashino K
    J Rheumatol; 1997 Apr; 24(4):708-13. PubMed ID: 9101506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of DL-sodium lactate infusion on excretion of purine bases and oxypurinol.
    Yamamoto T; Moriwaki Y; Takahashi S; Nasako Y; Higashino K
    Int J Clin Pharmacol Ther Toxicol; 1993 Dec; 31(12):588-92. PubMed ID: 8314359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allopurinol and xanthine nephropathy.
    Wyngaarden JB
    N Engl J Med; 1970 Aug; 283(7):371-2. PubMed ID: 5468407
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of bovine milk ingestion on urinary excretion of oxypurinol and uric acid.
    Kurajoh M; Ka T; Okuda C; Yamamoto A; Tsutsumi Z; Koyama H; Moriwaki Y; Yamamoto T
    Int J Clin Pharmacol Ther; 2011 Jun; 49(6):366-70. PubMed ID: 21612743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xanthine calculi in the patient with the Lesch-Nyhan syndrome associated with urinary tract infection.
    Oka T; Utsunomiya M; Ichikawa Y; Koide T; Takaha M; Mimaki T; Sonoda T
    Urol Int; 1985; 40(3):138-40. PubMed ID: 3925607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal xanthine stone in Lesch-Nyhan syndrome treated with allopurinol.
    Ogawa A; Watanabe K; Minejima N
    Urology; 1985 Jul; 26(1):56-8. PubMed ID: 4012980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxypurinol and purine bases.
    Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Hada T
    J Rheumatol; 2000 Sep; 27(9):2232-6. PubMed ID: 10990239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of angiotensin II infusion on renal excretion of purine bases and oxypurinol.
    Moriwaki Y; Yamamoto T; Tsutsumi Z; Takahashi S; Hada T
    Metabolism; 2002 Jul; 51(7):893-5. PubMed ID: 12077737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allopurinol or oxypurinol in heart failure therapy - a promising new development or end of story?
    Reyes AJ; Leary WP
    Cardiovasc Drugs Ther; 2005 Oct; 19(5):311-3. PubMed ID: 16382292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of furosemide on renal excretion of oxypurinol and purine bases.
    Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Hada T
    Metabolism; 2001 Feb; 50(2):241-5. PubMed ID: 11229436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.
    Chu WY; Annink KV; Nijstad AL; Maiwald CA; Schroth M; Bakkali LE; van Bel F; Benders MJNL; van Weissenbruch MM; Hagen A; Franz AR; Dorlo TPC; Allegaert K; Huitema ADR;
    Clin Pharmacokinet; 2022 Feb; 61(2):321-333. PubMed ID: 34617261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of urinary oxypurinol by high performance liquid chromatography-tandem mass spectrometry.
    Stocker SL; Franklin ME; Anderson JM; Pillans PI; Williams KM; McLachlan AJ; Day RO; Taylor PJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Sep; 878(25):2363-8. PubMed ID: 20702150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of allopurinol and its metabolite oxypurinol after oral administration of allopurinol alone or associated with benzbromarone in man. Simultaneous assay of hypoxanthine and xanthine by gas chromatography-mass spectrometry.
    Lartigue-Mattei C; Chabard JL; Ristori JM; Bussiere JL; Bargnoux H; Petit J; Berger JA
    Fundam Clin Pharmacol; 1991; 5(7):621-33. PubMed ID: 1778540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of amino acids on the excretions of purine bases and oxypurinol.
    Yamamoto T; Moriwaki Y; Takahashi S; Yamakita J; Higashino K
    Nephron; 1996; 73(1):41-7. PubMed ID: 8742955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two siblings with classical xanthinuria type 1: significance of allopurinol loading test.
    Ichida K; Yoshida M; Sakuma R; Hosoya T
    Intern Med; 1998 Jan; 37(1):77-82. PubMed ID: 9510406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.